Cardioactive glycosides exert positive inotropic effects on cardiomyocytes through the inhibition of Na + /K + -ATPase. We showed previously that in human hepatoma cells, digoxin and ouabain increase the rate of the mevalonate cascade and therefore have Na + /K + -ATPase-independent effects. In the present study we found that they increase the expression and activity of 3-hydroxy-3 methylglutaryl-CoA reductase and the synthesis of cholesterol in cardiomyocytes, their main target cells. Surprisingly this did not promote intracellular cholesterol accumulation. The glycosides activated the liver X receptor transcription factor and increased the expression of ABCA1 (ATPbinding cassette protein A1) transporter, which mediates the efflux of cholesterol and its delivery to apolipoprotein A-I. By increasing the synthesis of ubiquinone, another derivative of the mevalonate cascade, digoxin and ouabain simultaneously enhanced the rate of electron transport in the mitochondrial respiratory chain and the synthesis of ATP. Mice treated with digoxin showed lower cholesterol and higher ubiquinone content in their hearts, and a small increase in their serum HDL (high-density lipoprotein) cholesterol. The results of the present study suggest that cardioactive glycosides may have a role in the reverse transport of cholesterol and in the energy metabolism of cardiomyocytes.
INTRODUCTION
Cardioactive glycosides are used in the treatment of atrial fibrillation and chronic heart failure. Owing to their inhibition of Na + /K + -ATPase (EC 3.6.3.9), they increase the intracellular concentration of Na + , decrease the extrusion of Ca 2 + via the Na + /Ca 2 + exchanger and exert a positive inotropic effect in cardiomyocytes [1] . They also exert effects independently of Na + /K + -ATPase inhibition [2, 3] , in that they control the transcription of specific genes [4] and modulate the synthesis of steroid hormones [5, 6] . In human hepatoma cells, we observed that digoxin and ouabain increased the synthesis of cholesterol by up-regulating both the activity and the expression of HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) (EC 1.1.1.34), which is the rate-limiting enzyme of the mevalonate pathway. This event was mediated by the activation of the SREBP (sterol-regulatoryelement-binding protein)-2 and of the SCAP (SREBP-cleavageactivating protein) [7] .
The mevalonate pathway mediates the synthesis of sterols, such as cholesterol, and non-sterol isoprenoid metabolites, which are incorporated in the tail of ubiquinone. Both cholesterol and ubiquinone have critical roles in cardiovascular disease [8, 9] . Ubiquinone (or CoQ 10 ), the electron shuttle between NADH dehydrogenase (Complex I, EC 1.6.5.3), or succinateCoQ reductase (Complex II, EC 1.3.5.1), and ubiquinolcytochrome c reductase (Complex III, EC 1.10.2.2) [10] , is necessary for mitochondrial respiration and ATP synthesis. Ubiquinone is lower in the cardiomyocytes of patients with ventricular dysfunction [11] and low serum levels of ubiquinone are predictive of higher mortality in chronic heart failure [12] . Dietary supplementation with CoQ 10 has improved systolic function and haemodynamic parameters in those patients [13] .
Modulating the synthesis of cholesterol and ubiquinone in cardiomyocytes might thus have important implications on cardiac metabolism and function. Since digoxin and ouabain activate the mevalonate pathway in liver cells [7] , we set out to investigate whether they may also affect the levels of cholesterol and ubiquinone in cardiomyocytes, the main targets of this class of drugs.
at http://www.BiochemJ.org/bj/447/bj4470301add.htm), was cultured in Dulbecco's modified Eagle's medium containing 10 % (v/v) FBS (Sigma), 1 % (v/v) penicillin/streptomycin and 1 % (v/v) L-glutamine. The culture medium contained 32 μg/ml cholesterol, 8 μg/ml HDL (high-density lipoprotein) cholesterol, 13 μg/ml LDL (low-density lipoprotein) cholesterol and 55 μg/ml triacylglycerols. Total cholesterol, HDL cholesterol and triacylglycerols were measured with the OSR6516, OSR6187 and OSR61118 kits respectively (Olympus System Reagent), using an Olympus Analyzer spectrophotometer (Olympus Europa Holding). The results were calculated according to the titration curve of each kit. LDL cholesterol was calculated with the Friedewald formula.
Measurement of cholesterol and ubiquinone de novo synthesis
The de novo synthesis of cholesterol and ubiquinone was measured by radiolabelling cells with 1 μCi/ml [ 3 H]acetate (3600 mCi/mmol; Amersham GE Healthcare, Piscataway, NJ), or with 1 μCi/ml [ 14 C]mevalonic acid (67 mCi/mmol; Amersham GE Healthcare), as reported in [7] . Cholesterol 
Cytotoxicity assays
The release of LDH (lactate dehydrogenase) in the extracellular medium, a marker of cell damage, and the positivity to annexin V-FITC, a marker of apoptosis, were measured as reported previously [7] .
Measurement of HMGCR activity and expression
The activity and expression of HMGCR were measured in microsomal fractions collected by centrifugation of cell lysates at 40 000 rev./min in an optima L-90K Beckman Coulter ultracentrifuge using a 70.1 Ti rotor for 1 h (4 • C), as described previously [7] .
RT-PCR (real-time PCR)
Total RNA was extracted with TRIzol ® (Invitrogen); a 5 μg portion was reverse-transcribed by 200 units of M-MLV (Moloney murine leukaemia virus) enzyme (Invitrogen). Quantitative RT-PCR was carried out using IQ TM SYBR Green Supermix (Bio-Rad Laboratories), according to the manufacturer's instructions. The relative quantification of each sample was performed comparing the PCR products of each gene with the housekeeping gene product (actin), with the iQ TM 5 Optical System Software (BioRad Laboratories). Results were expressed in arbitrary units. For each gene, the expression in untreated cells was considered to be '1'. Primers sequences are shown in Supplementary Table S1 at http://www.BiochemJ.org/bj/447/bj4470301add.htm.
Isolation of mitochondria and measurement of Complex I-III activity
The activity of ubiquinone-dependent and ubiquinoneindependent Complex I-III was measured on non-sonicated extracted mitochondria as previously reported [14] .
ATP detection assay
The ATP level in mitochondria was measured with the ATP Bioluminescent Assay Kit (Sigma), using a Magic Lite Analyzer (Ciba Corning Diagnostic). ATP was quantified as arbitrary light units and converted into nmol of ATP per mg of mitochondrial proteins, according to a calibration curve set earlier.
Cholesterol loading and spectrophotometric measurement of intracellular cholesterol
The cholesterol loading was performed by preparing cholesterol-β-methyl-cyclodextrin complexes as described previously [7] . The amount of intracellular cholesterol was measured in cell lysates with the OSR6516 kit. The results were expressed as μg of cholesterol per mg of cell proteins.
Measurement of extracellular cholesterol
The amount of cholesterol in the cell culture medium after cholesterol loading was measured spectrophotometrically by means of the OSR6516 kit.
To evaluate cholesterol efflux, cells were incubated with 1 μCi/ml [ 3 H]cholesterol for 1 h, washed five times with PBS and grown in fresh medium for 24 h. The cell culture medium was collected, cholesterol was extracted in methanol/hexane and resolved by TLC [7] . 
Flow cytometry analysis
Cells were washed with PBS, detached with cell dissociation solution (Sigma), fixed with 0.2 ml of 2 % (w/v) paraformaldehyde, rinsed with 0.25 % PBS-BSA and incubated for 45 min at 4
• C with the anti-ABCA1 antibody (Abcam). After two washes in PBS-BSA, cells were incubated for 30 min at 4
• C with an anti-(rabbit FITC)-conjugated antibody, then washed again and resuspended in PBS-BSA. Control experiments included incubation with non-immune isotypic antibody, followed by the secondary antibody. Samples were analysed with a FACS-Calibur flow cytometer (Becton Dickinson), using a 530 nm band-pass filter. For each analysis, 100 000 events were collected and processed with Cell Quest software (Becton Dickinson).
EMSA (electrophoretic mobility-shift assay)
The probe containing the DR-4 (direct repeat response element-4) for LXR, validated with Genomatix Software (http://www. genomatix.de/; Munich, Germany), was: 5 -GCGACCCCAGTG-ATATCCCGTCGTC-3 . The putative DR-4 site is underlined. The probe was labelled with 50 μCi of [γ -32 P]ATP (3000 Ci/mmol; Amersham Bioscience), using a T4 polynucleotide kinase (Roche). A total of 10 μg of proteins from nuclear extracts were incubated for 20 min at 4
• C with the 32 P-labelled probe, as described previously [7] . As a control of specificity, nuclear extracts from cells stimulated with the LXR activator TO-901317 were incubated with a mutated labelled probe (5 -GCGACCTATTGTATATCTGTTCGTC-3 ) or with the wild-type labelled probe plus a 100-fold excess of wild-type unlabelled probe. The DNA-protein complex was separated on a nondenaturing 4 % polyacrylamide gel, then the gel was dried and autoradiographed after 72 h.
Chromatin immunoprecipitation
Cells were rinsed with fixation buffer [500 mM Hepes/KOH, pH 7.9, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA and 11 % (v/v) formaldehyde], washed twice with PBS, centrifuged for 5 min at 1000 g at 4
• C and resuspended in lysis buffer [50 mM Tris/HCl, pH 8.0, 5 mM EDTA and 1 % (w/v) SDS]. After sonication (five pulses of 10 s at a power setting of 10, using a SONOPULS Bandelin instrument), a 200 μl volume of each sample was taken as input. The remaining lysates were pretreated for 2 h at 4
• C with Protein G-Sepharose magnetic beads (Invitrogen), then divided into three portions (incubated with anti-LXRβ or anti-LXRα, with generic IgG or without any antibody respectively) and immunoprecipitated overnight at 4
• C. The recovered DNA was washed, eluted with the elution buffer [0.1 M NaHCO 3 and 1 % (w/v) SDS], heated at 65
• C for 6 h and incubated with proteinase K for 1 h at 55
• C. Samples were cleaned by Qiaquick columns (Qiagen) and analysed by RT-PCR. The putative LXRE (LXR response element) sites on the ABCA1 rat promoter, as well as the non-specific sequences upstream of the promoter, used as negative internal controls, were validated with the Genomatix Software (http://www.genomatix.de/). Primer sequences are reported in Supplementary Table S1 .
Treatment of mice and in vivo assays
The in vivo experiments were performed in conformity with the Public Health Service Policy on Human Care and Use of Laboratory Animals and were approved by the Institutional Review Board. Mice were housed in an environmentally controlled room (24 • C, 12 h light/dark cycle) and provided with food and fresh water ad libitum. A standard diet for mouse maintenance was used (Mucedola srl, 4RF21 Certificate PF1610). FVB male mice (1 month old) were injected daily intraperitoneally with 1 mg of digoxin/kg, diluted in 0.9 % NaCl solution, for 5 or 8 days. Before killing, mice were heparinized and anaesthetized with 250 mg of tribromoethanol/kg. Blood was collected through decapitation.
Hearts were excised and rinsed in ice-cold Dulbecco's PBS. Atria were removed, ventricular tissue and apex were collected in RNAlater solution (Ambion) or ice-cold 1 M NaCl and frozen at − 80
• C. RNA was extracted and used for RT-PCR experiments. Lipids were extracted from 50 mg of ventricular homogenates as described previously [16] . Cholesterol was measured spectrophotometrically with the OSR6516 kit (Olympus System Reagent) and the results were expressed as μg of cholesterol/mg of heart tissue. The amount of ubiquinone was determined spectrophotometrically [17] and the absorbance was converted into μmol of ubiquinone/mg of heart tissue, using a calibration curve prepared previously.
Plasma total cholesterol and HDL cholesterol were determined with OSR6516 and OSR6187 kits respectively (Olympus System Reagent) and the results were expressed as mg/100 ml. Plasma digoxin was quantified with the Access Digoxin Kit (Beckman Coulter) and the results were expressed as ng/ml.
Intracellular triacylglycerol measurement
The amount of triacylglycerol was measured in mouse heart homogenates and in H9c2 cell lysates using the Triglyceride Quantification Kit (Abcam). Results were expressed in nmol/mg of cell or tissue proteins, according to the calibration curve set previously.
Statistical analysis
All of the data in the text and Figures are provided as means + − S.D. The results were analysed by a one-way ANOVA and Tukey's test. P < 0.05 was considered significant. To ascertain whether the effects of digoxin and ouabain were limited to HMGCR, we studied other genes of the mevalonate pathway, under the transcriptional control of SREBP-2 [18] . Both drugs up-regulated HMGCS (3-hydroxy-3-methylglutaryl-CoA synthase) (Figure 2c ), although to a lower extent than HMGCR. We did not detect other effects exerted by either digoxin and ouabain in the analysed genes (Figure 2c ).
To confirm that glycosides specifically modulate the first steps of the mevalonate pathway, we measured the synthesis of cholesterol in cells labelled with Besides cholesterol, digoxin and ouabain also increased the synthesis of another mevalonate pathway derivative, ubiquinone (Figure 1 ), the only electron carrier between mitochondrial Complexes I or II and Complex III. Therefore glycosides enhanced the electron flow in mitochondria of H9c2 cells ( Figure 3a) ; this increase was found both in the presence of the Complex I inhibitor rotenone (when the electron transport relies entirely on ubiquinone) and in its absence (i.e. when the electron flow depends on Complex I plus ubiquinone). The enhanced electron flow resulted in increased levels of ATP, an effect prevented by the F 1 F o -ATP synthase inhibitor oligomycin (Figure 3b ).
Digoxin and ouabain prevent the intracellular accumulation of cholesterol
When cholesterol levels rise in mammalian cells, HMGCR activity is down-regulated [20] . When loaded with exogenous cholesterol (Figure 4a ), H9c2 cells had a low activity of HMGCR (Figure 4b ). Unexpectedly, in spite of the increased endogenous cholesterol synthesis (Figures 1 and 2 ), we detected low levels of intracellular cholesterol after treatment with digoxin and ouabain ( Figure 4a) . Moreover, when cells were treated with glycosides plus cholesterol, they showed lower amounts of intracellular cholesterol than cells treated with cholesterol alone (Figure 4a ). HMGCR activity remained high in the presence of digoxin and ouabain (Figure 4b ), which was consistent with the low level of intracellular cholesterol.
Of note, we observed a progressive cholesterol accumulation in the culture medium from cells treated with digoxin and ouabain (Figure 4c ).
Digoxin and ouabain promote the efflux of cholesterol via the ABCA1 transporter
To investigate whether digoxin and ouabain stimulate the efflux of intracellular cholesterol, we pulsed H9c2 cells with Figure  S5b) , which is consistent with mammalian cells in general [21, 22] . In a parallel set of experiments, we labelled cells with (Figure 5b ). Under these circumstances, digoxin and ouabain also promoted cholesterol efflux. Moreover, apoA-I protein further enhanced the efflux and glyburide decreased it.
ABCA1 was expressed in H9c2 cells at baseline and was increased by digoxin and ouabain, both in whole-cell lysates (Figure 5c ) and on the cell surface (Figure 5d ). ABCG1 and SR-BI, two other transporters involved in cholesterol efflux, were either only slightly increased by digoxin and ouabain (ABCG1) or not affected at all (SR-BI) (Supplementary Figure S6 at http://www.BiochemJ.org/bj/447/bj4470301add.htm).
Digoxin and ouabain increase the transcription of ABCA1 by activating LXR
To find out how glycosides increased the expression of ABCA1 and ABCG1, we investigated which transcription factors may upregulate these transporters.
The promoters of ABCA1 [23, 24] and ABCG1 [25] contain sterol-responsive elements, which are activated by the heterodimers LXRα-RXR (retinoid X receptor) and LXRβ-RXR. The total amount of LXRβ and LXRα was not affected by either glycosides or mevastatin (Figure 6a ). LXR did not bind to its DNA target sequence in untreated H9c2 cells (Figure 6b) . Conversely, digoxin and ouabain promoted the binding of LXR to DNA, an event prevented by mevastatin and mimicked by the LXR activator TO-901317 [24] (Figure 6b ). As shown by chromatin immunoprecipitation assays, glycosides induced the binding of either LXRα and LXRβ to the LXRE sequence of the ABCA1 promoter (Figure 6c ).
Mice treated with digoxin have a lower amount of cholesterol and a higher amount of ubiquinone in their hearts
The effects of digoxin were studied in mice treated for 5 and 8 days with 1 mg of the drug/kg per day. At the end of these time periods, blood digoxin levels were significantly higher when compared with untreated mice (Table 1 ) and within the accepted human therapeutic range [26, 27] . The drug increased HMGCR mRNA in a time-dependent fashion ( Figure 7a ) and decreased cholesterol content (Figure 7b ) in heart tissue. We did not detect significant differences in the serum levels of cholesterol in treated and untreated mice; however, HDL cholesterol was slightly higher in the treated group (Table 1) . A high degree of variability was observed in the levels of cardiac ubiquinone, in digoxin-treated mice and in controls. Individual variability notwithstanding, the hearts of animals treated with digoxin in general showed higher levels of ubiquinone.
Since LXR may increase the expression of several genes involved in the synthesis of fatty acids and triacylglycerols [28] , we set out to see whether these genes were activated in the hearts of digoxin-treated animals. We did not observe any changes in the expression of lipogenic genes (acetylCoA carboxylase, fatty acid synthase, glycerol-3-phosphate acyltransferase and stearoyl-CoA desaturase 1); only SREBP-1c was decreased after digoxin treatment (Figure 7d ). Intracellular triacylglycerol levels were highly variable, but did not differ in each experimental group (Figure 7e 
DISCUSSION
Cardioactive glycosides are specific inhibitors of Na + /K + -ATPase and positive inotropic drugs [1] . The impact of cardioactive glycosides on cholesterol metabolism in cardiac tissue has not been investigated. We used H9c2 cells, which share some ultrastructural features with skeletal muscle [29] [30] [31] , but retain the key electrophysiological and biochemical properties of cardiomyocytes [29, 32] , making them a useful tool for the in vitro investigation of cardioactive drugs. In each experiment one lane was loaded with distilled water (-) in place of cell extracts. The LXR activator TO-901317 (TO; 100 nM for 24 h) was added as a positive control. As a control of specificity, the nuclear extracts of TO-901317-stimulated cells were incubated with a mutated probe (TO mut) or with a 100-fold excess of non-radioactive wild-type probe (TO cold). (c) Chromatin immunoprecipitation assays. The binding of LXRα and LXRβ to the ABCA1 promoter was measured as described in the Experimental section; the immunoprecipitated DNA was analysed by RT-PCR, using primers for the LXREs in the ABCA1 promoter or for an upstream region, chosen as a negative control. Results are means + − S.D. (n = 4). *P < 0.01 compared with control.
Digoxin and ouabain enhanced the activity of the mevalonate pathway in a dose-and time-dependent manner in these cells. This increase was accompanied by the up-regulation of the ratelimiting enzyme HMGCR, which is under the transcriptional control of SREBP-2. Although SREBP-2 induces a transcriptional activation of several enzymes involved in cholesterol biosynthesis [18] , in H9c2 cells only the HMGCR and HMGCS genes were up-regulated by both digoxin and ouabain. Such specificity suggests that glycosides may act not only by simply activating SREBP-2 [7] , but also by recruiting other transcription factors and/or co-activators, which in turn co-operate with SREBP-2 on HMGCR and HMGCS promoters.
The effects of glycosides on the HMGCR step, or on one of the first steps in the mevalonate cascade, were confirmed by functional assays: the increase in cholesterol was indeed prevented by the HMGCR inhibitor mevastatin in cells labelled with or treated with the inhibitor of squalene synthase, zaragozic acid. Both cholesterol and ubiquinone, the mevalonate pathway products increased by digoxin and ouabain, play an undisputed role in cardiovascular disease and therapy [8, 9, 11, 13] .
Glycosides increased the synthesis of ubiquinone in H9c2 cells, thus enhancing the efficiency of mitochondrial electron transport and ATP synthesis. Both adequate intracellular Ca 2 + levels and a constant supply of ATP are necessary to support an efficient contractile performance. The increase of intracellular Ca 2 + is a well-documented effect of digoxin [1] [2] [3] ; the increase in aerobic metabolism and ATP synthesis observed in the present study may represent an additional mechanism by which digoxin exerts its positive inotropic effects.
Cholesterol levels also affect other crucial cellular functions in cardiomyocytes: increased plasma membrane cholesterol modifies the affinity of Na + /K + -ATPase for inhibitors and alters the activity of Ca 2 + -ATPase, Na + /Ca 2 + -exchanger and Na + /K + -ATPase, three pumps that critically affect intracellular Ca 2 + levels [8] . As digoxin and ouabain increase the synthesis of cholesterol, one might expect that these cells 'fill up' with cholesterol. Such occurrence, however, has never been described in patients Male FVB mice (1 month old) were treated with 1 mg of digoxin/kg for 5 days (n = 6) or 8 days (n = 6). The control group (CTRL; n = 10) was treated with saline solution. Animals were killed at the end of treatment, and heart tissue was homogenized, frozen and subjected to the following investigations. (a) Total RNA was extracted, reverse-transcribed and amplified by RT-PCR to check HMGCR expression. Results are means + − S.D. *P < 0.05 compared with control. Amounts of cholesterol (chol) (b) and ubiquinone (ubiq) (c) were measured spectrophotometrically in heart homogenates, after the appropriate extraction [16, 17] A crucial mechanism of cholesterol efflux in mammalian tissues is its active transport via the ABC transporter ABCA1, which transfers cholesterol from the cytosol to apoA-I and mediates the first step of HDL assembly [23, 33, 34] . Interestingly, both digoxin and ouabain increased the amount of ABCA1 in H9c2 cells. In addition, ABCG1, a second transporter which mediates the efflux of cholesterol from the cells, was slightly increased. As we worked with a culture medium that contains HDLs, we hypothesized that glycosides might promote the delivery of cholesterol to the apoA-I present in the culture medium through ABCA1. When we used the ABCA1 inhibitor glyburide, cholesterol efflux decreased to control levels, even under maximal stimulation (i.e. when digoxin and ouabain were co-incubated with apoA-I): this suggests that in H9c2 cells, most of the glycoside-induced cholesterol efflux is mediated by ABCA1, whereas ABCG1 plays a secondary role.
Multiple sterol-responsive elements, activated by LXRα-RXR and LXRβ-RXR heterodimers in response to oxysterols, are contained in the promoter of the ABCA1 gene [23, 24] . Giving the cell a cholesterol load induces the transcriptional activity of LXRs, suggesting that free cholesterol, or a cholesterolderived metabolite produced within cells, can up-regulate ABCA1 [34] . We hypothesize that a similar mechanism might also work with glycosides, which in our hands increased the synthesis of cholesterol, the binding of LXR on DNA target sequences and the activation of the ABCA1 promoter.
To our knowledge this is the first report that shows that cardioactive glycosides stimulate the reverse transport of cholesterol by increasing the expression of ABCA1 and the delivery of cholesterol to apoA-I, and therefore facilitate one of the first steps in the assembly of HDLs. This event may have physiological relevance, since an efficient reverse cholesterol transport and high levels of HDLs are protective factors against cardiovascular disease.
The concentration of digoxin used in our in vitro experiments (10 nM) falls within the clinically accepted therapeutic range [26, 27] . At these concentrations, the well-known inotropic effects of glycosides are mainly mediated by their binding to the α2 subunit of Na + /K + -ATPase [35] , which in rats has a higher affinity for ouabain than α1 subunit [36] . Since α1 and α2 subunit levels were equal in H9c2 cells, it is likely that in our model the Na + /K + -ATPase-dependent effects of glycosides were mediated by the interaction with the α2 subunit. H9c2 cells mirror rat tissues, which have a mix of ouabain-insensitive (i.e. containing solely the α1 isoform) Na + /K + -ATPases and ouabain-sensitive (i.e. containing the α2 and α3 isoforms) ones [37] . Rodents are more resistant than humans to the effects of digoxin on Na + /K + -ATPase [37, 38] . Nonetheless, after a few days of treatment, in our animal models, digoxin reached the same levels as the accepted clinically therapeutic ones in humans. As such, it began to exert its effects on the mevalonate pathway in hearts, as the increased expression of HMGCR, the progressive decrease in cholesterol and increase in ubiquinone synthesis would indicate. Since in the liver, LXR up-regulates SREBP-1c and co-operates with it to promote the synthesis of fatty acids and triacylglycerols [28] , we set out to investigate whether these events occurred in the heart as well. Differently from what happens in the liver, in our model digoxin decreased the expression of SREBP-1c. Such a decrease may prevent the up-regulation of lipogenic genes and the accumulation of triacylglycerols in cardiac myocytes, making the onset of a lipid-induced cardiomyopathy an unlikely event.
The present study sheds some new light on the metabolic effects of glycosides in cardiac myocytes. By enhancing the activity of the mevalonate pathway, glycosides increase the cellular levels of ubiquinone, the aerobic metabolism and the synthesis of ATP of the cells, three events critical in the control of contractile performance. In addition, glycosides finely control the levels of cholesterol in the cell. On one hand, they provide cells with a metabolite (cholesterol) necessary for the maintenance of membrane homoeostasis and the proper conformation and activity of transporters, channels and receptors. On the other, they prevent the intracellular accumulation of the same metabolite and facilitate its delivery to HDLs. Beside being used as therapeutic agents, ouabain-and digoxin-like substances are also endogenously produced; acting at nanomolar/picomolar concentrations, these endogenous glycosides have been implicated in the control of blood pressure and in the cardiovascular remodelling of chronic heart failure [39] . One could surmise that the same effects observed with exogenously administered glycosides might be exerted by the ones that are endogenously produced. From this perspective, glycosides might indeed be novel regulators of cholesterol homoeostasis. 
